seed
Stage
1
Investors
About
Vitaeris Inc. is a clinical-stage biotechnology company developing clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody for treating chronic active antibody-mediated rejection in solid organ transplant patients and other chronic inflammatory diseases.
Explore Vitaeris Inc.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.